Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy

Cancer Research

Volumn 71, Issue 15, 2011, Pages 5134-5143

  Hubert, Pascale ^a,b   Heitzmann, Adèle ^a,b   Viel, Sophie ^a,b   Nicolas, André ^a   Sastre Garau, Xavier ^a   Oppezzo, Pablo ^c,d   Pritsch, Otto ^c,d   Osinaga, Eduardo ^c,d   Amigorena, Sebastian ^a,b  

^a INSTITUT CURIE   (France)

^b PSL RESEARCH UNIVERSITY   (France)

^c DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^d INSTITUT PASTEUR DE MONTEVIDEO   (Uruguay)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FC RECEPTOR; MONOCLONAL ANTIBODY CHI TN; RITUXIMAB; TN ANTIGEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IMMUNOLOGICAL SYNAPSE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LOW DRUG DOSE; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOLOGICAL SYNAPSES; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEUTROPHILS; OVARIAN NEOPLASMS; RECEPTORS, IGG; TUMOR MICROENVIRONMENT;

EID: 79960963888     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4222     Document Type: Article

References (44)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57. (Pubitemid 41486396)
2. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317-27.
3. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010;116:3705-14.
4. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6. (Pubitemid 30208162)
5. Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 2008;112:1205-13.
6. de Haij S, Jansen MJH, Boross P, Beurskens FJ, Bakema JE, Bos DL, et al. In vivo cytotoxicity of Type I CD20 antibodies critically depends on Fc receptor ITAM signalling. Cancer Res 2010;70:3209-17.
7. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8. (Pubitemid 34525533)
8. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7. (Pubitemid 46606207)
9. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, MissaleG, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-96.
10. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003;9:5866-73. (Pubitemid 38018069)
11. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10:5650-5. (Pubitemid 39180938)
12. Springer GF. T and Tn, general carcinoma autoantigens. Science 1984;224:1198-206.
13. Itzkowitz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, Bigbee WL, et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 1989;49:197-204. (Pubitemid 19024432)
14. Beuzelin-Yvraut M, Bourguignat A, Phillips E, Roseto A, Osinaga E. Immunocytological analysis of the Tn associated antigen 83D4 in serous effusions from patients with cancer: comparison with Tn soluble glycoprotein. J Clin Pathol 1995;48:433-7.
15. Croce MV, Rabassa ME, Price MR, Segal-Eiras A. MUC1 mucin and carbohydrate associated antigens as tumor markers in head and neck squamous cell carcinoma. Pathol Oncol Res 2001;7:284-91. (Pubitemid 34174694)
16. Li Q, Anver MR, Butcher DO, Gildersleeve JC. Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines. Mol Cancer Ther 2009;8:971-9.
17. Ju T, Cummings RD. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci U S A 2002;99:16613-8. (Pubitemid 36034021)
18. Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, et al. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res 2008;68:1636-46. (Pubitemid 351416547)
19. Babino A, Oppezzo P, Bianco S, Barrios E, Berois N, Navarrete H, et al. Tn antigen is a pre-cancerous biomarker in breast tissue and serum in n-nitrosomethylurea-induced rat mammary carcinogenesis. Int J Cancer 2000;86:753-9. (Pubitemid 30350188)
20. Oppezzo P, Osinaga E, Tello D, Bay S, Cantacuzene D, Irigoín F, et al. Production and functional characterization of two mouse/human chimeric antibodies with specificity for the tumor-associated Tn-antigen. Hybridoma 2000;19:229-39. (Pubitemid 30622624)
21. Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 2004;103:2677-82. (Pubitemid 38393024)
22. Charpin C, Pancino G, Osinaga E, Bonnier P, Lavaut MN, Allasia C, et al. Monoclonal antibody 83D4 immunoreactivity in human tissues: cellular distribution and microcytophotometric analysis of immunoprecipitates on tissue sections. Anticancer Res 1992;12:209-23.
23. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-9.
24. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
25. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115-23.
26. Fung PY, Madej M, Koganty RR, Longenecker BM. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 1990;50:4308-14. (Pubitemid 20225670)
27. Lo-Man R, Vichier-Guerre S, Bay S, Dériaud E, Cantacuzène D, Leclerc C. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope. J Immunol 2001;166:2849-54. (Pubitemid 32173527)
28. Powers JF, Sladek NE. Cytotoxic activity relative to 4- hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats. Cancer Res 1983;43:1101-06. (Pubitemid 13160030)
29. Chan KK, Hong PS, Tutsch K, Trump DL. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508. Cancer Res 1994;54:6421-9.
30. Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 1998;395:82-6. (Pubitemid 28420234)
31. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010;18:160-70.
32. Nakada H, Inoue M, Numata Y, Tanaka N, Funakoshi I, Fukui S, et al. Epitopic structure of Tn glycophorin A for an anti-Tn antibody (MLS 128). Proc Natl Acad Sci U S A 1993;90:2495-9. (Pubitemid 23078654)
33. Avichezer D, Springer GF, Schechter B, Arnon R. Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model. Int J Cancer 1997;72:119-27. (Pubitemid 27314648)
34. Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC, et al. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 2006;314:304-8. (Pubitemid 44571976)
35. Ando H, Matsushita T, Wakitani M, Sato T, Kodama-Nishida S, Shibata K, et al. Mouse-human chimeric anti-Tn IgG1 induced antitumor activity against Jurkat cells in vitro and in vivo. Biol Pharm Bull 2008;31:1739-44.
36. Osinaga E, Bay S, Tello D, Babino A, Pritsch O, Assemat K, et al. Analysis of the fine specificity of Tn-binding proteins using synthetic glycopeptide epitopes and a biosensor based on surface plasmon resonance spectrospcopy. FEBS Letters 2000;469:24-8. (Pubitemid 30119862)
37. Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, et al. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 1998;101:429-41. (Pubitemid 28067341)
38. Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 2007;13:644-53. (Pubitemid 46225372)
39. van Spriel AB, Leusen JH, van Egmond M, Dijkman HB, Assmann KJ, Mayadas TN, et al. Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation. Blood 2001;97:2478-86. (Pubitemid 32291496)
40. Joshi T, Ganesan LP, Cheney C, Ostrowski MC, Muthusamy N, Byrd JC, et al. The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma. PLoS One 2009;4:e4208.
41. Haynes NM, Hawkins ED, Li M, McLaughlin NM, Hämmerling GJ, Schwendener R, et al. CD11c+dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J Immunol 2010;185:532-41.
42. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-38. (Pubitemid 24194147)
43. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010;120:1111-24.
44. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8. (Pubitemid 46348738)